AP2007003919A0 - Glycerol branched polyethylene glycol human growthhormone conjugates, process for their prepation a nd methods of use thereof - Google Patents
Glycerol branched polyethylene glycol human growthhormone conjugates, process for their prepation a nd methods of use thereofInfo
- Publication number
- AP2007003919A0 AP2007003919A0 AP2007003919A AP2007003919A AP2007003919A0 AP 2007003919 A0 AP2007003919 A0 AP 2007003919A0 AP 2007003919 A AP2007003919 A AP 2007003919A AP 2007003919 A AP2007003919 A AP 2007003919A AP 2007003919 A0 AP2007003919 A0 AP 2007003919A0
- Authority
- AP
- ARIPO
- Prior art keywords
- growthhormone
- prepation
- conjugates
- methods
- polyethylene glycol
- Prior art date
Links
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 title 3
- 102000002265 Human Growth Hormone Human genes 0.000 title 1
- 108010000521 Human Growth Hormone Proteins 0.000 title 1
- 239000000854 Human Growth Hormone Substances 0.000 title 1
- 239000002202 Polyethylene glycol Substances 0.000 title 1
- 229920001223 polyethylene glycol Polymers 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pregnancy & Childbirth (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60594504P | 2004-08-31 | 2004-08-31 | |
PCT/IB2005/002939 WO2006024953A2 (en) | 2004-08-31 | 2005-08-25 | Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AP2007003919A0 true AP2007003919A0 (en) | 2007-02-28 |
Family
ID=35708806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2007003919A AP2007003919A0 (en) | 2004-08-31 | 2005-08-25 | Glycerol branched polyethylene glycol human growthhormone conjugates, process for their prepation a nd methods of use thereof |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP1789092A2 (en) |
JP (1) | JP2008511610A (en) |
KR (1) | KR20070042567A (en) |
CN (1) | CN101010105A (en) |
AP (1) | AP2007003919A0 (en) |
AR (1) | AR050851A1 (en) |
AU (1) | AU2005278903A1 (en) |
BR (1) | BRPI0515118A (en) |
CA (1) | CA2577999A1 (en) |
CR (1) | CR8942A (en) |
EA (1) | EA200700380A1 (en) |
EC (1) | ECSP077281A (en) |
GT (1) | GT200500235A (en) |
IL (1) | IL181085A0 (en) |
MA (1) | MA28908B1 (en) |
MX (1) | MX2007002441A (en) |
NL (1) | NL1029828C2 (en) |
NO (1) | NO20071322L (en) |
PE (1) | PE20060654A1 (en) |
TN (1) | TNSN07078A1 (en) |
TW (1) | TW200621291A (en) |
UY (1) | UY29088A1 (en) |
WO (1) | WO2006024953A2 (en) |
ZA (1) | ZA200701802B (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
CA2296770A1 (en) | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
IL144259A0 (en) | 1999-01-14 | 2002-05-23 | Bolder Biotechnology Inc | Methods for making proteins containing free cysteine residues |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
EP1834963A1 (en) * | 2006-03-13 | 2007-09-19 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
US20090117077A1 (en) * | 2006-05-12 | 2009-05-07 | Dong-A Pharm. Co., Ltd. | Polyethylene glycol-interferon alpha conjugate |
JP2008069073A (en) * | 2006-09-12 | 2008-03-27 | Yokohama Tlo Co Ltd | Lactoferrin conjugate and its manufacturing method |
KR101079993B1 (en) | 2006-11-17 | 2011-11-04 | 동아제약주식회사 | Polyethylene glycol-G-CSF conjugate |
CL2008002399A1 (en) | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c. |
RU2483081C2 (en) * | 2008-07-23 | 2013-05-27 | Ханми Сайенс Ко.,Лтд.,Kr | Polypeptide complex containing non-peptidyl polymer, having three functional ends |
MX2011001167A (en) | 2008-07-31 | 2011-04-12 | Pharmaessentia Corp | Peptide-polymer conjugates. |
SG195531A1 (en) * | 2008-10-10 | 2013-12-30 | Bionic Ear Inst | Biodegradable polymer - bioactive moiety conjugates |
US8535655B2 (en) | 2008-10-10 | 2013-09-17 | Polyactiva Pty Ltd. | Biodegradable polymer—bioactive moiety conjugates |
SI2340271T1 (en) | 2008-10-10 | 2019-08-30 | Polyactiva Pty Ltd. | Polymer-bioactive agent conjugates |
US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
ES2610356T3 (en) | 2009-02-03 | 2017-04-27 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising the same |
US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
US8841249B2 (en) | 2009-08-06 | 2014-09-23 | Novo Nordisk A/S | Growth hormones with prolonged in-vivo efficacy |
CN101831067A (en) * | 2010-05-31 | 2010-09-15 | 王二新 | Polyethylene glycol ester conjugate and application thereof in medicine preparation |
EP2446898A1 (en) | 2010-09-30 | 2012-05-02 | Laboratorios Del. Dr. Esteve, S.A. | Use of growth hormone to enhance the immune response in immunosuppressed patients |
CN102367290B (en) * | 2011-04-26 | 2013-05-08 | 厦门赛诺邦格生物科技有限公司 | Chain-functionalized multi-level branched polyethylene glycol and synthesis method thereof |
EP2947111B1 (en) * | 2013-01-17 | 2018-03-07 | Xiamen Sinopeg Biotech Co., Ltd. | Monofunctional branched polyethyleneglycol and bio-related substance modified by same |
CN104877127B (en) | 2015-06-23 | 2017-11-10 | 厦门赛诺邦格生物科技股份有限公司 | A kind of eight arms polyethyleneglycol derivative, preparation method and its bio-related substance of modification |
CA2964390A1 (en) | 2014-11-06 | 2016-05-12 | Pharmaessentia Corporation | Dosage regimen for pegylated interferon |
ES2905105T3 (en) | 2017-12-29 | 2022-04-07 | Hoffmann La Roche | Procedure for Providing a PEGylated Protein Composition |
EP3731871B1 (en) * | 2017-12-29 | 2023-10-04 | F. Hoffmann-La Roche AG | Process for providing pegylated protein composition |
SI3731873T1 (en) * | 2017-12-29 | 2022-05-31 | F. Hoffmann-La Roche Ag | Process for providing pegylated protein composition |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2147192A (en) * | 1991-06-28 | 1993-01-25 | Genentech Inc. | Method of stimulating immune response using growth hormone |
JP3092531B2 (en) * | 1996-11-05 | 2000-09-25 | 日本油脂株式会社 | Method for producing imidyl succinate-substituted polyoxyalkylene derivative |
CA2296770A1 (en) * | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
JP3921781B2 (en) * | 1998-02-12 | 2007-05-30 | 日本油脂株式会社 | Carboxyl group-containing polyoxyalkylene compound |
IL144259A0 (en) * | 1999-01-14 | 2002-05-23 | Bolder Biotechnology Inc | Methods for making proteins containing free cysteine residues |
JP2005525302A (en) * | 2001-11-20 | 2005-08-25 | ファルマシア・コーポレーション | Chemically modified human growth hormone conjugates |
EP1546235B1 (en) * | 2002-09-09 | 2021-10-20 | Nektar Therapeutics | Water-soluble polymer alkanals |
JP4412461B2 (en) * | 2002-11-20 | 2010-02-10 | 日油株式会社 | Modified bio-related substance, production method thereof and intermediate |
WO2004060406A2 (en) * | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Polymeric reagents comprising a ketone or a related functional group |
EP3593820A1 (en) * | 2003-05-23 | 2020-01-15 | Nektar Therapeutics | Peg derivatives containing two peg chains |
-
2005
- 2005-08-25 MX MX2007002441A patent/MX2007002441A/en unknown
- 2005-08-25 WO PCT/IB2005/002939 patent/WO2006024953A2/en active Application Filing
- 2005-08-25 AU AU2005278903A patent/AU2005278903A1/en not_active Abandoned
- 2005-08-25 EP EP05784225A patent/EP1789092A2/en not_active Withdrawn
- 2005-08-25 JP JP2007529040A patent/JP2008511610A/en active Pending
- 2005-08-25 BR BRPI0515118-0A patent/BRPI0515118A/en not_active IP Right Cessation
- 2005-08-25 AP AP2007003919A patent/AP2007003919A0/en unknown
- 2005-08-25 EA EA200700380A patent/EA200700380A1/en unknown
- 2005-08-25 CA CA002577999A patent/CA2577999A1/en not_active Abandoned
- 2005-08-25 CN CNA2005800291171A patent/CN101010105A/en active Pending
- 2005-08-25 KR KR1020077004912A patent/KR20070042567A/en not_active Application Discontinuation
- 2005-08-26 PE PE2005000991A patent/PE20060654A1/en not_active Application Discontinuation
- 2005-08-29 UY UY29088A patent/UY29088A1/en not_active Application Discontinuation
- 2005-08-29 AR ARP050103612A patent/AR050851A1/en unknown
- 2005-08-30 NL NL1029828A patent/NL1029828C2/en not_active IP Right Cessation
- 2005-08-30 TW TW094129583A patent/TW200621291A/en unknown
- 2005-08-30 GT GT200500235A patent/GT200500235A/en unknown
-
2007
- 2007-01-31 IL IL181085A patent/IL181085A0/en unknown
- 2007-02-26 CR CR8942A patent/CR8942A/en not_active Application Discontinuation
- 2007-02-27 EC EC2007007281A patent/ECSP077281A/en unknown
- 2007-02-27 TN TNP2007000078A patent/TNSN07078A1/en unknown
- 2007-02-28 MA MA29724A patent/MA28908B1/en unknown
- 2007-02-28 ZA ZA200701802A patent/ZA200701802B/en unknown
- 2007-03-09 NO NO20071322A patent/NO20071322L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NL1029828A1 (en) | 2006-03-01 |
BRPI0515118A (en) | 2008-07-01 |
PE20060654A1 (en) | 2006-08-12 |
EP1789092A2 (en) | 2007-05-30 |
TW200621291A (en) | 2006-07-01 |
MA28908B1 (en) | 2007-10-01 |
UY29088A1 (en) | 2006-03-31 |
WO2006024953A2 (en) | 2006-03-09 |
MX2007002441A (en) | 2007-05-04 |
AR050851A1 (en) | 2006-11-29 |
ECSP077281A (en) | 2007-03-29 |
AU2005278903A1 (en) | 2006-03-09 |
CN101010105A (en) | 2007-08-01 |
IL181085A0 (en) | 2007-07-04 |
JP2008511610A (en) | 2008-04-17 |
WO2006024953A3 (en) | 2007-01-18 |
GT200500235A (en) | 2006-03-21 |
CA2577999A1 (en) | 2006-03-09 |
TNSN07078A1 (en) | 2008-06-02 |
KR20070042567A (en) | 2007-04-23 |
CR8942A (en) | 2007-08-16 |
NL1029828C2 (en) | 2006-10-20 |
NO20071322L (en) | 2007-05-29 |
ZA200701802B (en) | 2008-08-27 |
EA200700380A1 (en) | 2007-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP2007003919A0 (en) | Glycerol branched polyethylene glycol human growthhormone conjugates, process for their prepation a nd methods of use thereof | |
EP2485686B8 (en) | Tibial implant base | |
GB0607544D0 (en) | Knee prothesis | |
EP2083774A4 (en) | Therapeutic intra-vaginal devices&methods | |
ZA200807961B (en) | Methods for preparing complex multivalent immunogenic conjugates | |
GB2426201B (en) | Knee prosthesis | |
EP2005806A4 (en) | Patient setup using tomosynthesis techniques | |
GB0510194D0 (en) | Knee prosthesis | |
PT1765292T (en) | Abuse-deterrent drug formulations | |
EP2088951A4 (en) | Apparatus and methods for multipolar tissue welding | |
EP2506881A4 (en) | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy | |
EP2194922A4 (en) | Knee prosthesis | |
IL195839A0 (en) | New protein conjugates and methods for their preparation | |
EP1871293A4 (en) | Apparatus and methods for delivering prostheses to luminal bifurcations | |
HK1137347A1 (en) | Method of radio-sensitizing tumors using a radio-sensitizing agent | |
EP2240165A4 (en) | Soluble hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same | |
IL193636A0 (en) | Process for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants | |
EP1718335A4 (en) | Drug conjugates | |
ZA200806765B (en) | Bladder cancer treatment by using E09 and propylene glycol | |
GB0609058D0 (en) | Knee prosthesis | |
EP2495258A4 (en) | Catechol polyethylene glycol derivative and protein or peptide conjugates, and method for preparing same | |
EP2018873A4 (en) | Prophylactic/therapeutic agent for cancer | |
GB0510886D0 (en) | Foreskin prosthesis | |
EP2222328A4 (en) | Method of administering conjugates | |
GB0724360D0 (en) | Method for preparing protein conjugates |